Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 13/20 | 0.44 |
| ▸ | CNR2 | P34972 | 12/20 | 0.44 |
| ▸ | AKT1 | P31749 | 3/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | PHLPP1 | O60346 | 1/20 | 0.39 |
| ▸ | ILK | Q13418 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3694612 | 0.81 | CNR2 (0.42) | CNR1CNR2 | |
| SCHEMBL4567339 | 0.81 | CNR1 (0.46) | CNR1CNR2ACHE | |
| SCHEMBL3701630 | 0.75 | PKM (0.47) | CNR1CNR2 | |
| SCHEMBL25230502 | 0.74 | SHBG (0.52) | CNR1CNR2 | |
| SCHEMBL3705499 | 0.74 | CNR2 (0.44) | CNR1CNR2 | |
| SCHEMBL3693693 | 0.73 | CNR2 (0.45) | CNR1CNR2 | |
| SCHEMBL27602008 | 0.71 | CNR2 (0.48) | CNR1CNR2 | |
| SCHEMBL6716285 | 0.71 | CNR2 (0.43) | CNR1CNR2ACHE | |
| SCHEMBL17430879 | 0.70 | ALOX15 (0.45) | — | |
| SCHEMBL4567343 | 0.70 | ACHE (0.31) | AKT1PDPK1PHLPP1ILKACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138315-A1 | Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation | IMMUGEN PHARMACEUTICALS, INC. (US) | 2004-07-15 | — | — | US | claimed |
| WO-2002026224-A9 | METHODS AND COMPOUNDS FOR INHIBITING EICOSANOID METABOLISM AND PLATELET AGGREGATION | IMMUGEN PHARMACEUTICALS INC (US) | 2003-02-20 | — | — | WO | claimed |
| US-20020137802-A1 | Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation | IMMUGEN PHARMACEUTICALS, INC. | 2002-09-26 | — | — | US | claimed |
| WO-2002026224-A2 | METHODS AND COMPOUNDS FOR INHIBITING EICOSANOID METABOLISM AND PLATELET AGGREGATION | IMMUGEN PHARMACEUTICALS, INC. (US) | 2002-04-04 | — | — | WO | claimed |
| CN-1652766-A | Topical formulations of resorcinol and cannabinoids and methods of administration thereof | IMMUGEN PHARMACEUTICALS INC (US) | 2005-08-10 | — | — | CN | disclosed |
| US-20040138315-A1 | Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation | IMMUGEN PHARMACEUTICALS, INC. (US) | 2004-07-15 | — | — | US | disclosed |
| WO-2004016254-A2 | CONTRACEPTIVE METHODS AND FORMULATIONS | IMMUGEN PHARMACEUTICALS, INC. (US) | 2004-02-26 | — | — | WO | disclosed |
| US-20030232101-A1 | Topical formulations of resorcinols and cannibinoids and methods of use | IMMUGEN PHARMACEUTICALS, INC. | 2003-12-18 | — | — | US | disclosed |
| WO-2003080043-A1 | TOPICAL FORMULATIONS OF RESORCINOLS AND CANNIBINOIDS AND METHODS OF USE | IMMUGEN PHARMACEUTICALS, INC. (US) | 2003-10-02 | — | — | WO | disclosed |
| WO-2002026224-A9 | METHODS AND COMPOUNDS FOR INHIBITING EICOSANOID METABOLISM AND PLATELET AGGREGATION | IMMUGEN PHARMACEUTICALS INC (US) | 2003-02-20 | — | — | WO | disclosed |
| US-20020137802-A1 | Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation | IMMUGEN PHARMACEUTICALS, INC. | 2002-09-26 | — | — | US | disclosed |
| WO-2002026224-A2 | METHODS AND COMPOUNDS FOR INHIBITING EICOSANOID METABOLISM AND PLATELET AGGREGATION | IMMUGEN PHARMACEUTICALS, INC. (US) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137802-A1 | Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation | PTGS1, PTGIS, PTGES | CNR1 5/4885CNR2 9/4885AKT1 1456/4885 |
| US-20030232101-A1 | Topical formulations of resorcinols and cannibinoids and methods of use | CNR2, CNR1, CXCL8 | CNR1 2/4885CNR2 1/4885AKT1 771/4885 |
| US-20040138315-A1 | Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation | PTGS1, PTGIS, PTGES | CNR1 5/4885CNR2 9/4885AKT1 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.